GlassScriptPhysician profile
Naveed Ali
NPI 1134569692
$435.28
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $38.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $139.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $73.74 | 2019-2020 | |
| Genzyme Corporation | $63.69 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $23.00 | 2019 | |
| Karyopharm Therapeutics INC. | $21.74 | 2020 | |
| Jazz Pharmaceuticals INC. | $18.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.12 | 2019 | |
| Merck Sharp & Dohme LLC | $16.10 | 2019 | |
| Lilly USA, LLC | $15.79 | 2019 | |
| Incyte Corporation | $15.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.35 | 2019 | |
| Amgen INC. | $13.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.